1-10 of 10
Laura McBride
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Two Year Update of Phase II Trial of Pembrolizumab, Lenalidomide and Dexamethasone As Post -Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Meena Bansal, DO, David S. Siegel, Jaeil Ahn, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Andrew L. Pecora, MD, Elli Gourna Paleoudis, PhD, Scott D. Rowley, MD, Michele L. Donato, MD, Robert Korngold, PhD, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Noa Biran, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1911.
https://doi.org/10.1182/blood-2019-125155
Published: 2019
Journal Articles

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Noa Biran, MD, Tracy Andrews, PhD, Rena Feinman, PhD, David H. Vesole, MD PhD, Joshua R Richter, MD, Joshua Zenreich, Palka Anand, RN, BSN, CCRP, Laura McBride, RN, BSN, OCN, Kristin Ivanovski, RN, BSN, CCRP, Robert Korngold, PhD, David Siegel, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1831.
https://doi.org/10.1182/blood.V130.Suppl_1.1831.1831
Published: 2017
Journal Articles

Real-World Outcomes with Panobinostat in Patients with Relapsed/Refractory Multiple Myeloma

Noa Biran, MD, David H. Vesole, MD PhD, Shijia Zhang, MD PhD, Joshua R. Richter, MD, Yen-Hong Kuo, PhD, Linda Schmidt, RN BSN MSN OCN CNL, Laura McBride, RN, BSN, OCN, CCRP, Palka Anand, BSN, Kristin Ivanovski, RN, Amy Pierre, RN, MSN, APN, Susan Kumka, RN, MSN, APN, Carmela Cuccurullo, RN, MSN, APN, David S. Siegel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5685.
https://doi.org/10.1182/blood.V128.22.5685.5685
Published: 2016
Journal Articles

Vorinostat in Combination with Lenalidomide (L) and Dexamethasone (d) in Multiple Myeloma Patients Refractory to Previous Lenalidomide-Containing Regimens: Results of a Phase IIb Trial

Larysa Sanchez, MD, Yucai Wang, MD PhD, Laura McBride, RN, BSN, OCN, CCRP, Elizabeth Bilotti, MSN, David H. Vesole, MD, Joshua Richter, MD, Noa Biran, MD, Palka Anand, Kristin Ivanovski, Ann McNeill, ANP, David Siegel, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4264.
https://doi.org/10.1182/blood.V126.23.4264.4264
Published: 2015
Journal Articles

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib

Clinical Trials & Observations
Paul G. Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Jacob Laubach, Daniel Sullivan, Melissa Alsina, Robert Schlossman, Irene M. Ghobrial, Deborah Doss, Nora Loughney, Laura McBride, Elizabeth Bilotti, Palka Anand, Lisa Nardelli, Sandra Wear, Gail Larkins, Min Chen, Mohamad H. Zaki, Christian Jacques, Kenneth C. Anderson
Journal: Blood
Blood (2013) 121 (11): 1961–1967.
https://doi.org/10.1182/blood-2012-08-450742
Published: 2013
Journal Articles

Salvage Therapy with Vorinostat, Lenalidomide, and Dexamethasone (ZRD) in Lenalidomide/Dexamethasone Relapsed/Refractory Multiple Myeloma,

Joshua R. Richter, MD, Elizabeth Bilotti, MSN, RN, Laura McBride, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Palka Anand, Ann McNeill, Urszula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD, David S. Siegel, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3986.
https://doi.org/10.1182/blood.V118.21.3986.3986
Published: 2011
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or In Combination with Low-Dose Dexamethasone In Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib

Paul G Richardson, MD, David Siegel, MD, PhD, Rachid Baz, MD, Susan L. Kelley, MD, Nikhil C. Munshi, MD, Daniel Sullivan, MD, Melissa Alsina, MD, Deborah Doss, RN, OCN, Laura McBride, Gail Larkins, RN, Maria Lizza, BS, Xin Yu, Mohamed Zaki, MD, Christian J. Jacques, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2010) 116 (21): 864.
https://doi.org/10.1182/blood.V116.21.864.864
Published: 2010
Journal Articles

Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma

David Samuel diCapua Siegel, MD, PhD, Laura McBride, Elizabeth Bilotti, MSN, RN, Linda Schmidt, Zhijie Gao, MD, Madiha Tufail, MD, Nikoletta Lendvai, MD, PhD, Ann McNeill, Kristen Donadio, Karly Olivo, Urzula Bednarz, Thorsten Graef, MD, PhD, David H. Vesole, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3065.
https://doi.org/10.1182/blood.V116.21.3065.3065
Published: 2010
Journal Articles

A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.

Paul Richardson, David Siegel, Rachid Baz, Susan L. Kelley, Nikhil C. Munshi, Daniel Sullivan, Laura McBride, Deborah Doss, Gail Larkins, Christian Jacques, Arlene Donaldson, Kenneth C. Anderson
Journal: Blood
Blood (2009) 114 (22): 301.
https://doi.org/10.1182/blood.V114.22.301.301
Published: 2009
Journal Articles

Final Results of a Phase I Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in Patients with Advanced Multiple Myeloma.

Paul G. Richardson, Constantine S. Mitsiades, Kathleen Colson, Eileen Reilly, Laura McBride, Judy Chiao, Linda Sun, Justin L. Ricker, Syed Rizvi, Carol Oerth, Barbara Atkins, Ivy Fearen, Kenneth C. Anderson, David S. Siegel
Journal: Blood
Blood (2007) 110 (11): 1179.
https://doi.org/10.1182/blood.V110.11.1179.1179
Published: 2007